Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant DCX for Stage II/III Esophageal Squamous Cell Carcinoma
NCT02915965Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2016
- Primary completion
- Oct 2018
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, cisplatin and capecitabine in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sun Yat-sen University. Primary endpoint: Overall Survival Rate at 2 years. Status: unknown.
02
Drugs
docetaxelcisplatincapecitabine
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT02915965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02915965.